Universal Antibody Lock
Higher Selectivity, Safer Treatments
Systemic Neutralization Leads to On-target Toxicity
Noticing that antibody drugs can effectively cure diseases but also cause severe adverse effects due to on-target toxicity, PrecisemAb is committed to creating safer, more effective antibody treatment options for patients through our novel Universal Antibody Lock technology.
Disease-directed Masking Technology for Antibody
Our Universal Antibody Lock technology could “inactivate” an antibody’s binding ability by “locking” the binding site. The binding ability of the Lock-antibody is limited in healthy tissues until the Lock-antibody encounters active protease near the disease region, which cleaves the “lock” from the antibody. The cleaved Lock-antibody is designed to be conditionally-activated and neutralize target antigens to inhibit the disease progression. Therefore, our antibody lock technology can effectively enhance antibody drugs’ selectivity in the disease area and consequently reduce side effects caused by on-target toxicity.
Widely Applicable to Antibody Drugs
Universal Antibody Lock has been successfully applied to the Rheumatoid Arthritis drug, anti-TNFα antibody. Lock-anti-TNFα antibody is selectively activated only in the disease site and presents similar pharmacokinetics and therapeutic efficacy as the marketed drug Infliximab, while Lock-anti-TNFα antibody effectively minimizes the side effects, such as interference in immunity against Listeria infection in mice models.
Unlocking Precision in Antibody Therapy
A Disease-directed Antibody Masking Technology
Six Product Features
Patent Map
Antibody Lock For The Inactivation Of Protein Drug (PCT/US2014/039821)
How We Design the Antibody Lock？
We use computer simulation to predict and select the most optimized lock sequence for your antibody. We also construct Lock-antibody and test Lock function to confirm the applicability for your antibody.
